ArticleAnnals of surgical oncology2026
Exploring the Limits of Perigastric Surgery in Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei: A Functional Burden with Preserved Oncologic Outcomes.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is the standard treatment for pseudomyxoma peritonei (PMP), and complete cytoreduction remains essential for prognosis. While gastrectomy has traditionally represented a major threshold of surgical aggressiveness, the functional impact of increasingly extensive perigastric dissection is not well defined.
methodsWe retrospectively analyzed 110 consecutive patients who underwent CRS and HIPEC for appendiceal PMP between 2016 and 2024. Perigastric procedures were categorized into five Gastric Cytoreductive Levels (GCLs) based on the extent of vascular sacrifice. Postoperative gastrointestinal recovery was compared among stomach-preserving procedures (GCL1-4), whereas morbidity and oncologic outcomes were evaluated across all five groups. Independent predictors of delayed oral refeeding were assessed through multivariable logistic regression, and a predictive nomogram was developed.
resultsGastrointestinal recovery worsened with increasing extent of stomach-preserving perigastric dissection. Patients in GCL4 experienced delayed oral intake, longer dependence on parenteral nutrition, and prolonged hospitalization compared with those undergoing less extensive procedures; nasogastric tube removal was also delayed. Major morbidity, 30 day mortality, and long-term survival were similar across all groups. Female sex, longer operative duration, and GCL4 independently predicted delayed oral refeeding. The nomogram demonstrated good discrimination and calibration.
conclusionsIncreasingly extensive perigastric cytoreduction is associated with impaired postoperative gastric recovery while maintaining acceptable morbidity and oncologic outcomes. The predictive nomogram-although exploratory-may help to anticipate postoperative nutritional needs and support tailored recovery strategies after extensive CRS and HIPEC for PMP.
Indexed as
Identifiers
42104034What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.